RECORD // Company

Drugs Made In America Acquisition Corp.

Built 2026-11-22T00:27:29Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001477932-26-007043

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$1,244,8123 months ended 2026-09-3010-Q2026-11-160001477932-26-0070432026-11-22 00:27 UTCReport an error
Cash and cash equivalents$17,011at 2026-09-3010-Q2026-11-160001477932-26-0070432026-11-22 00:27 UTCReport an error
Contract liabilities, noncurrent (from an earlier report)$6,900,000at 2025-12-3110-K2026-04-150001213900-26-0441392026-11-22 00:27 UTCReport an error

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0002028614
Ticker
DMAA
CUSIP
G2847J104
Record ID
sx:sec:0002028614

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

23 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 00:27 UTCReport an error
SIC industry6770 Blank Checks2026-11-16SEC EDGAR company profile2026-11-22 00:27 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 00:27 UTCReport an error
Business address420 LEXINGTON AVENUE, SUITE 1402, NEW YORK, NY, 101702026-11-16SEC EDGAR company profile2026-11-22 00:27 UTCReport an error
ExchangesNasdaq, Nasdaq, Nasdaq2026-11-16SEC EDGAR company profile2026-11-22 00:27 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$5,940,6432025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:27 UTCReport an error
Total assets (at 2025-12-31)$239,918,8472025-12-3110-K, XBRL Assets2026-11-22 00:27 UTCReport an error
Stockholders' equity (at 2025-12-31)$-7,263,9812025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:27 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$6,1372025-12-3110-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents2026-11-22 00:27 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-539,1872025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:27 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive (filed 2026-10-21)Agreement. On October 13, 2026, Drugs Made In America Acquisition Corp. (the “Company”) and Power Analytics Global Corp, a Delaware corporation (“PAGC”), entered into Amendment No. 1 (the “Amendment”) to their Amended and Restated Definitive Merger Agreement dated as of September 8, 2026 (the “Merger Agreement”). The Amendment was approved by the boards of directors of both parties. Standalone Closing Valuation The Merger Agreement provides for a Closing Valuation of US$2,850,000,000, determined on an asset basis and including PAGC’s proposed acquisition of APQC Inc and the UltraSolar intellectual property (the “APQC Acquisition”), and makes completion of the APQC Acquisition a condition to…2026-10-21SEC EDGAR 8-K 0001213900-26-111421 (text as filed, excerpt)2026-11-22 00:27 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-21)The independent firm previously approved to render the fairness opinion contemplated by Section 6.5(a) of the Merger Agreement determined that the intellectual property valuation required by the assignment would have called for a dual opinion, with a separate intellectual property evaluator added to complete it. As a result, no opinion was issued, and the Company and that firm agreed to terminate the engagement effective October 2, 2026. On October 12, 2026, following the written approval of the Company’s board of directors, the Company’s independent directors engaged Joel A. Gallo, acting in his individual capacity as an independent evaluator and financial advisor, under an Independent…2026-10-21SEC EDGAR 8-K 0001213900-26-111421 (text as filed, excerpt)2026-11-22 00:27 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-09-14)Background As previously disclosed, on April 29, 2026, Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company” or “DMAA”), entered into a Definitive Merger Agreement (the “Original Agreement”) with Power Analytics Global Corp, a Delaware corporation engaged in the business of artificial intelligence, advanced analytics and quantum-resistant security solutions (“PAGC”). The Original Agreement was amended by Amendment No. 1 dated April 30, 2026, Amendment No. 2 dated April 30, 2026 and Omnibus Amendment No. 3 dated July 14, 2026 (together with the Original Agreement, the “Existing Agreement”). The Original Agreement, Amendment No. 1 and Amendment No. 2 were…2026-09-14SEC EDGAR 8-K 0001213900-26-099738 (text as filed, excerpt)2026-11-22 00:27 UTCReport an error
Largest institutional holder #1 (13F as filed): MIZUHO SECURITIES USA LLC$42,830,1132026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:27 UTCReport an error
Largest institutional holder #2 (13F as filed): Karpus Management, Inc.$26,708,2512026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:27 UTCReport an error
Largest institutional holder #3 (13F as filed): Polar Asset Management Partners Inc.$12,204,9002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:27 UTCReport an error
Largest institutional holder #4 (13F as filed): WOLVERINE ASSET MANAGEMENT LLC$8,861,7902026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:27 UTCReport an error
Largest institutional holder #5 (13F as filed): HIGHBRIDGE CAPITAL MANAGEMENT LLC$8,616,4252026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:27 UTCReport an error
Largest institutional holder #6 (13F as filed): First Trust Capital Management L.P.$8,375,7882026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:27 UTCReport an error
Largest institutional holder #7 (13F as filed): HEIGHTS CAPITAL MANAGEMENT, INC$6,902,0842026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:27 UTCReport an error
Largest institutional holder #8 (13F as filed): Westchester Capital Management, LLC$6,196,0632026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:27 UTCReport an error
Largest institutional holder #9 (13F as filed): ARISTEIA CAPITAL, L.L.C.$3,727,5002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:27 UTCReport an error
Largest institutional holder #10 (13F as filed): SONA ASSET MANAGEMENT (US) LLC$1,733,7672026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:27 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.